During the past decade, treatment strategies for patients with advanced prostate cancer
involving stage IV (T4N0M0, N1M0 or M1) hormone‐sensitive prostate cancer and recurrent …

Simple Summary Drug resistance is prevalent in many types of cancer and decreases
patient survival. The taxanes are anti-mitotic chemotherapeutic agents, widely used since …

Prostate cancer (PCa) is one of the most common cancers in European males. Although
therapeutic approaches have changed in recent years, and several new drugs have been …

ProBio is the first outcome-adaptive platform trial in prostate cancer utilizing a Bayesian
framework to evaluate efficacy within predefined biomarker signatures across systemic …

Patients with metastatic castration-resistant prostate cancer (mCPRC) now have an
unprecedented number of approved treatment options, including chemotherapies …

In last years several improvements have been made in the management of prostate cancer
(PCa). Androgen receptor (AR) is considered the main driver in PCa growth and progression …

Taxanes–docetaxel and cabazitaxel–are the most active chemotherapy drugs currently used
for the treatment of metastatic castration-resistant prostate cancer (mCRPC). However …

Analysis of circulating tumor cells (CTCs) collected from patient's blood offers a broad range
of opportunities in the field of precision oncology. With new advances in profiling technology …

Purpose: We evaluated the association of PSA and androgen receptor splice variant-7 (AR-
V7) transcript levels in patients' blood with time to treatment failure (TTF) and overall survival …

Prostate cancer remains one of the leading causes of cancer death in men worldwide. In the
past decade, several new treatments for advanced prostate cancer have been approved …